Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
63 Cards in this Set
- Front
- Back
Additive effects |
Drug interactions in which the effect of a combination of two or more drugs with similar actions is equivalent to the sum of the individual effects of the same drug given alone. For example, 1+1=2 |
|
Adverse drug event |
Any undesirable occurrence related to administering or failing to administer a prescribed medication |
|
Adverse drug reaction |
Any unexpected unintended undesired or excessive response to a medication given a therapeutic dosages |
|
Adverse effects |
A general term for any undesirable effect that are a direct response to one or more drugs |
|
Agonist |
A drug that binds to and stimulates the activity of one or more receptors in the body |
|
Allergic reaction |
An immunologic hypersensitivity reaction resulting from the unusual sensitivity of a patient to a particular medication, a type of adverse drug event |
|
Antagonist |
A drug that binds to and inhibits the activity of one or more receptors in the body. Are also called inhibitors |
|
Antagonistic effects |
Drug interactions in which the effect of a combination of two or more drugs is less than the sum of the individual effects of the same drugs given alone (1+1=<2); it is usually caused by an antagonizing, (blocking or reducing) effect of one drug on another |
|
Bioavailability |
A measure of the extent of drug absorption for a given drug in route. From 0% to 100% |
|
Biotransformation |
One or more biochemical reactions involving a parent drug; occurs mainly in the liver and produces a metabolite that is either inactive or active. Also known as metabolism |
|
Blood-brain barrier |
The barrier system that restricts the passage of various chemicals and microscopic entities between the bloodstream and the central nervous system. It allows for passage of essential substances such as oxygen |
|
Chemical name |
The name that describes the chemical composition and molecular structure of a drug |
|
Contraindication |
Any condition especially one related to a disease state or patient characteristic including current or recent drug therapy which renders a particular form of treatment improper or undesirable |
|
Cytochrome P 450 |
The general name for a large class of enzymes that play a significant role in drug metabolism and drug interactions |
|
Dependence |
A state in which there is a compulsive or chronic need as for a drug |
|
Dissolution |
The process by which solid forms of drug disintegrate in the gastrointestinal tract and become soluble before becoming absorbed into the circulation |
|
Drug |
Any chemical that affects the physiologic processes of a living organism |
|
Drug actions |
The processes involved in the interaction between a drug and body cells also called mechanism of action |
|
Drug classification |
A method of grouping drugs, may be based on structure or therapeutic use |
|
Drug effects |
The physiologic reaction of the body to a drug. They can be therapeutic or toxic and describe how the body is affected as a whole by the drug |
|
Drug-induced teratogenesis |
The development of congenital abnormalities or defects in the developing fetus caused by the Toxic effect of drugs |
|
Drug interaction |
Alteration in the pharmacologic OR pharmacokinetic activity of a given drug caused by the presence of one or more additional drugs, it is usually related to effects on the enzymes required for metabolism of the involved with drugs |
|
Duration of action |
The length of time the concentration of a drug in the blood or tissues is sufficient to elict a response |
|
Enzymes |
Protein molecules that catalyze one or more of a variety of biochemical reactions including those related to the body's physiologic processes as well as those related to drug metabolism |
|
First pass effect |
The initial metabolism in the liver of a drug absorbed from the gastrointestinal tract before the drug reaches systemic circulation through the bloodstream |
|
Generic name |
The name given to a drug by the United States adopted names Council. Also called the non-proprietary name. This name is much shorter and simpler than the chemical name and is not protected by trademark |
|
Glucose-6-phosphate dehydrogenase (G6PD) deficiency |
A hereditary condition in which red blood cells break down when the body is exposed to certain drugs |
|
Half life |
In pharmacokinetics the time required for half of an administered dose of drug to be eliminated from the body or the time it takes for the blood level of a drug to be reduced by 50% |
|
Idiosyncratic reaction |
An abnormal and unexpected response to a medication other than an allergic reaction that is peculiar to an individual patient |
|
Incompatibility |
The characteristic that causes two parental drugs or solutions to undergo a reaction when mixed or given together that results in the chemical deterioration of at least one of the drugs |
|
Intra-arterial |
Within an artery |
|
Intra-articular |
Within a joint |
|
Intrathecal |
Within a sheath |
|
Medication error |
Any preventable adverse drug event involving inappropriate medication use by a patient or Healthcare professional, it may or may not cause patient harm |
|
Medication use process |
The prescribing dispensing and administering of medications and the monitoring of those effects |
|
Metabolite |
A chemical form of a drug that is the product of one or more biochemical reactions involving the parent drug. Have pharmacologic activity of their own even if the parent drug is inactive |
|
Onset of action |
The time required for a drug to elicit a therapeutic response after dosing |
|
P-glycoprotein |
A transporter protein that moves drugs out of cells and into the gut urine or bile |
|
Parent drug |
The chemical form of a drug that is administered before it is metabolized by the body into its active or inactive metabolites. |
|
Peak effect |
The time required for a drug to reach its maximum therapeutic response in the body |
|
Peak level |
The maximum concentration of a drug in the body after Administration usually measured in a blood sample for therapeutic drug monitoring |
|
Pharmaceutics |
The science of preparing and dispensing drugs including dosage form design |
|
Pharmacodynamics |
The study of the biochemical and physiological reactions of drugs at the their sites of activity. It examines of physicochemical properties of drugs and their pharmacologic interactions with bodies receptors |
|
Pharmacoeconomics |
The study of economic factors impacting the cost of drug therapy |
|
Pharmacognosy |
The study of drugs that are obtained from natural plant and animal sources |
|
Pharmacokinetics |
The study of what happens to a drug from the time it gets put into the body until the parent drug and all metabolites have left the body |
|
Pharmacology |
The broadest term for the study or science of drugs |
|
Pharmacotherapeutics |
The treatment of pathologic conditions through the use of drugs |
|
Prodrug |
An inactive drug dosage form that is converted to an active metabolite by various biochemical reactions once it is inside the body |
|
Receptor |
And molecular structure within or on the outer surface of a cell bind specific substances and one or more corresponding cellular effects occur as a result of this drug interaction |
|
Steady state |
The physiologic state in which the amount of drug removed via elimination is equal to the amount of drug absorbed with each dose |
|
Substrates |
Substances on which an enzyme Acts |
|
Synergistic effects |
Drug interactions in which the effect of a combination of two or more drugs with similar actions is greater than the sum of the individual effects of the same drugs given alone. For example 1+1=>2 |
|
Therapeutic drug monitoring |
The process of measuring drug levels to identify a patient's drug exposure and to allow a justment of dosages with the goals of maximizing therapeutic effects and minimizing toxicity |
|
Therapeutic effect |
The desired or intended effect of a particular medication |
|
Therapeutic index |
The ratio between the toxic and therapeutic concentrations of a drug |
|
Tolerance |
Reduced response to a drug after prolonged use |
|
Toxic |
The quality of being poisonous |
|
Toxicity |
The condition of producing adverse bodily effects due to the poisonous qualities |
|
Toxicology |
The study of poisons including toxic drug effects and applicable treatments |
|
Trade name |
The commercial name given to a drug product by its manufacturer also called the proprietary name |
|
Trough level |
The lowest concentration of drug reached in the body after it falls from its peak level usually measured in a blood sample for therapeutic drug monitoring |
|
Pharmacogenomics |
The study of influence of genetic factors And response that results in the absence overabundance or insufficiency of drug metabolizing enzymes |